New eye drug regimen aims to cut injection frequency for PCV patients
NCT ID NCT07461441
First seen Mar 26, 2026 · Last updated Jun 12, 2026 · Updated 12 times
Summary
This study tests a personalized treat-and-extend approach using faricimab for people newly diagnosed with polypoidal choroidal vasculopathy (PCV), a form of wet age-related macular degeneration. The goal is to see if this regimen can safely extend the time between eye injections to 16 weeks or more. About 50 participants will receive faricimab injections, with the treatment interval adjusted based on their individual response, and will be followed for 96 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yeungnam university medical center
RECRUITINGDaegu, Namgu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.